HAL (France)open access
Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process
Suicide, Antidepressants, Adverse events, 0, Generalized anxiety disorder, Escitalopram
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 246790
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.